Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1

Status

Withdrawn 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Other 1

Conditions

Pancreatic Neoplasms 2Opioid-Induced Constipation 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × methylnaltrexone × Clear all
NCT04083651 2021-05-07

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04151719 2021-05-07

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT00858754 2019-11-29

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Bausch Health Americas, Inc.

Phase 4 Withdrawn
Other

Opioid-Induced Constipation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡